Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: Further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP)

Journal of Pediatrics

Volumn 148, Issue 6, 2006, Pages

  Schmidt, Barbara ^a   Roberts, Robin S ^a   Fanaroff, Avroy ^a   Davis, Peter ^a   Kirpalani, Haresh M ^a   Nwaesei, Chuks ^a   Vincer, Michael ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; OXYGEN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDEMA; EXTREMELY LOW BIRTH WEIGHT; FEMALE; HUMAN; INFANT; LOGISTIC REGRESSION ANALYSIS; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OXYGENATION; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33744902653     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.01.047     Document Type: Article

References (15)

1. Schmidt B., Davis P., Moddemann D., Ohlsson A., Roberts R.S., Saigal S., et al. Long-term effects of indomethacin prophylaxis in extremely low birth weight infants. N Engl J Med 344 (2001) 1966-1972
2. Fowlie P.W., and Davis P.G. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev (2002) CD000174
3. Brown E.R. Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. J Pediatr 95 (1979) 865-866
4. Rojas M.A., Gonzalez A., Bancalari E., Claure N., Poole C., and Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 126 (1995) 605-610
5. Todd D.A., Jana A., and John E. Chronic oxygen dependency in infants born at 24-32 weeks' gestation. the role of antenatal and neonatal factors. J Paediatr Child Health 33 (1997) 402-407
6. Marshall D.D., Kotelchuck M., Young T.E., Bose C.L., Kruyer L., O'Shea T.M., and North Carolina Neonatologists Association. Risk factors for chronic lung disease in the surfactant era. a North Carolina population-based study of very low birth weight infants. Pediatrics 104 (1999) 1345-1350
7. Bancalari E. Changes in the pathogenesis and prevention of chronic lung disease of prematurity. Am J Perinatol 18 (2001) 1-9
8. Gournay V., Savagner C., Thiriez G., Kuster A., and Roze J.-C. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 359 (2002) 1486-1488
9. Schmidt B., Wright L.L., Davis P., Solimano A., Roberts R.S., and Indomethacin Prophylaxis in Preterms Investigators. Ibuprofen prophylaxis in preterm neonates. Lancet 360 (2002) 492
10. Lassus P., Viinikka L., Ylikorkala O., Pohjavuori M., and Andersson S. Pulmonary prostacyclin is associated with less severe respiratory distress in preterm infants. Early Hum Dev 67 (2002) 11-18
11. Gerdes J.S., Harris M.C., and Polin R.A. Effects of dexamethasone and indomethacin on elastase, alpha 1-proteinase inhibitor, and fibronectin in bronchoalveolar lavage fluid from neonates. J Pediatr 113 (1988) 727-731
12. Yaseen H., al Umran K., Ali H., Rustum M., Darwich M., and al-Faraidy A. Effects of early indomethacin administration on oxygenation and surfactant requirement in low birth weight infants. J Trop Pediatr 43 (1997) 42-46
13. Van Overmeire B., Van de Broek H., Van Laer P., Weyler J., and Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 138 (2001) 205-211
14. McCurnin D.C., Yoder B.A., Coalson J., Grubb P., Kerecman J., Kupferschmid J., et al. Effect of ductus ligation on cardiopulmonary function in premature baboons. Am J Respir Crit Care Med 172 (2005) 1569-1574
15. Laughon M.M., Simmons M.A., and Bose C.L. Patency of the ductus arteriosus in the premature infant. Is it pathologic? Should it be treated?. Curr Opin Pediatr 16 (2004) 146-151